Skip to main content
TAKARA BIO INC. logo

TAKARA BIO INC. — Investor Relations & Filings

Ticker · 4974 ISIN · JP3460200003 LEI · 529900OUPLSGTCWC5447 T Manufacturing
Open in API
Filings indexed 72 across all filing types
Latest filing 2022-11-11 Report Publication Anno…
Country JP Japan
Listing T 4974

About TAKARA BIO INC.

https://www.takarabio.com/?srsltid=AfmB…

Takara Bio Inc. is a biotechnology company that develops and supplies a wide range of high-quality, innovative tools for life science research. Its portfolio includes kits, reagents, and instruments that support investigations into gene discovery, regulation, and function. In addition to research products, the company provides comprehensive services, including single-cell analysis, stem cell services, and contract development and manufacturing (CDMO) services, particularly for the regenerative medicine sector. Takara Bio is also actively engaged in the development of gene-based therapies, conducting clinical trials for diseases such as cancer. The company's mission is to accelerate scientific discovery and contribute to human health through its advanced biotechnologies.

Recent filings

Filing Released Lang Actions
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically accompanying a Quarterly Report (第２四半期報告書). While it references a quarterly report, the document itself is a formal regulatory filing confirming the accuracy of the financial statements by the CEO and CFO. Given the specific nature of this regulatory confirmation filing in the Japanese market, it falls under the general regulatory filings category.
2022-11-11 Japanese
四半期報告書－第21期第2四半期(令和4年7月1日－令和4年9月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan. It contains detailed financial statements, including the balance sheet, income statement, and cash flow statement for the second quarter of the fiscal year ending March 31, 2023. It is a comprehensive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report (IR). H1 2023
2022-11-11 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act, specifically related to a correction of a Securities Report (有価証券報告書). In the Japanese regulatory context, this is a formal filing submitted to the Kanto Local Finance Bureau to confirm the accuracy of a previously filed report. Since it is a specific regulatory filing required by law that does not fit into the categories of a full annual report or a simple announcement, it is classified as a Regulatory Filing (RNS). FY 2022
2022-09-16 Japanese
訂正有価証券報告書－第20期(令和3年4月1日－令和4年3月31日)
Annual Report Classification · 100% confidence The document is a '訂正有価証券報告書' (Amended Securities Report) for Takara Bio Inc. It contains detailed financial tables, historical data, and corporate information for the fiscal year ending March 31, 2022. In the Japanese regulatory context, an '有価証券報告書' (Yuuka Shouken Houkokusho) is the equivalent of a 10-K annual report. Since this is a comprehensive financial report containing actual financial statements and analysis, it is classified as a 10-K. FY 2022
2022-09-16 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act, specifically related to a correction of a Securities Report (有価証券報告書). Since it is a regulatory filing confirming the accuracy of a previously filed report and does not fit into the specific categories of annual reports or earnings releases, it is classified as a general regulatory filing. FY 2021
2022-09-16 Japanese
訂正有価証券報告書－第19期(令和2年4月1日－令和3年3月31日)
Annual Report Classification · 100% confidence The document is a Japanese 'Yukashoken Hokokusho' (Annual Securities Report), which is the Japanese equivalent of a 10-K. It contains detailed financial statements, management discussion, and corporate information for the fiscal year ending March 31, 2021. The header explicitly identifies it as an 'Annual Securities Report' (有価証券報告書) and includes the business period (第19期). FY 2021
2022-09-16 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.